



Antiparasitic Treatment and Experimental Pharmacotherapy of Echinococcosis

Guest Editors:

Dr. María Celina Elissondo

Instituto de Investigaciones en
Producción Sanidad y Ambiente
(IIPROSAM CONICET-UNMdP),
Facultad de Ciencias Exactas y
Naturales–Universidad Nacional
de Mar del Plata, Centro
Científico Tecnológico Mar del
Plata–CONICET, Mar del Plata,
Argentina

Dr. Andrew Hemphill

Institute of Parasitology,
Faculties of Veterinary Medicine
and Medicine, University of
Berne, Länggass-Strasse 122,
3012 Berne, Switzerland

Deadline for manuscript
submissions:

closed (11 December 2023)

Message from the Guest Editors

Echinococcosis is a parasitic disease caused by cestodes of the genus *Echinococcus*. They cause a variety of diseases in humans: cystic echinococcosis, alveolar echinococcosis, and neotropical echinococcosis. The World Health Organization recognized them as “Neglected Tropical Diseases”.

Pharmacological treatment of echinococcosis is applicable to the various stages of *Echinococcus* spp.-related infections, in the intermediate host (including humans) and in the definitive host (domestic or wild animals). Antiparasitic drugs can kill or delay the development of the stages of *Echinococcus* spp. However, the type of drugs or treatment schedules may be different for the various stages and the various diseases.

In this Special Issue, we welcome the submission of full articles and review articles presenting novel concepts regarding the pharmacological treatment of echinococcosis including human and animal anti-parasitic treatment, in vitro and in vivo drug screening, experimental animal models of echinococcosis, pharmacotechnical strategies to improve the efficacy of albendazole, drug discovery and potential drug targets, natural products, and Phytomedicine.

